Tasaki M [94] showed that in a murine lung cancer (LLC) model, combined treatment with IL-7 and IL-12 promoted the activation of CD8+ T cells, which had a better effect on CD8+ T cell activation than the control group expressing IL-12 alone. This evidence concerns the gene CD8A and lung carcinoma.